|
|
Volumn 9 Suppl 3, Issue , 2009, Pages
|
|
Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
DRUG DERIVATIVE;
LENALIDOMIDE;
THALIDOMIDE;
ACUTE GRANULOCYTIC LEUKEMIA;
CHROMOSOME DELETION;
CLINICAL TRIAL;
DISEASE COURSE;
GENETICS;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
KARYOTYPING;
METHODOLOGY;
MYELODYSPLASTIC SYNDROME;
ONCOLOGY;
REVIEW;
RISK;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
CHROMOSOME DELETION;
CLINICAL TRIALS AS TOPIC;
DISEASE PROGRESSION;
HUMANS;
IMMUNOSUPPRESSION;
KARYOTYPING;
LEUKEMIA, MYELOID, ACUTE;
MEDICAL ONCOLOGY;
MYELODYSPLASTIC SYNDROMES;
RISK;
THALIDOMIDE;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 74049153904
PISSN: None
EISSN: 19380712
Source Type: Journal
DOI: 10.3816/clm.2009.s.028 Document Type: Review |
|
Times cited : (9)
|
|
References (16)
|
